APO-ENTECAVIR TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
18-01-2023
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
ENTECAVIR
Beschikbaar vanaf:
APOTEX INC
ATC-code:
J05AF10
INN (Algemene Internationale Benaming):
ENTECAVIR
Dosering:
0.5MG
farmaceutische vorm:
TABLET
Samenstelling:
ENTECAVIR 0.5MG
Toedieningsweg:
ORAL
Eenheden in pakket:
30
Prescription-type:
Prescription
Therapeutisch gebied:
NUCLEOSIDES AND NUCLEOTIDES
Product samenvatting:
Active ingredient group (AIG) number: 0151648001; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2012-11-23
Productkenmerken
_APO-ENTECAVIR (Entecavir Tablets) _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 52_
PRODUCT MONOGRAPH
PR
APO-ENTECAVIR
Entecavir Tablets
Tablets 0.5 mg
USP
Antiviral
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Preparation:
November 23, 2012
Date of Revision:
January 11, 2023
Submission Control Number: 271047
_APO-ENTECAVIR (Entecavir Tablets) _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT INFORMATION
.........................................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................................
3
CONTRAINDICATIONS..................................................................................................................
3
WARNINGS AND PRECAUTIONS
..................................................................................................
3
ADVERSE REACTIONS
..................................................................................................................
7
DRUG INTERACTIONS
................................................................................................................
11
DOSAGE AND ADMINISTRATION
...............................................................................................
12
OVERDOSAGE
............................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.................................................................................
13
STORAGE AND STABILITY
..........................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................. 20
PART II: SCIENTIFIC INFORMATION
......................................................................................
22
PHARMAC
Lees het volledige document
